Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.

Tommaso Francesco AielloOlivier PeyronyMariana ChumbitaPatricia MonzóCarlos LoperaPedro Puerta-AlcaldeLaura MagnanoFrancesc Fernández-AvilésGenoveva CuestaMontse TusetJosep MensaJordi EsteveMaria Angeles MarcosAlex SorianoCarolina Garcia-Vidal

Published in: Influenza and other respiratory viruses (2024)

Patients with hematologic malignancies and non-severe COVID-19 who received nirmatrelvir/ritonavir experienced faster decrease in viral load and shorter viral shedding. Furthermore, besides the advantage of oral administration, nirmatrelvir/ritonavir administration reduced the need of hospital admission.

Keyphrases

sars cov
respiratory syndrome coronavirus
antiretroviral therapy
emergency department
healthcare
early onset
coronavirus disease
adverse drug
drug induced
clinical evaluation